When thinking of the implementation of NGS as reflex testing at diagnosis of NS-NSCLC patients, we need to consider the biomarkers currently mandatory in practice, in addition to those that may be asked for when using targeted therapies in development (such as NRG1 and NUT), and for future new therapies [8]. Here, NRG1 is linked to non-small cell lung carcinoma.